Keyphrases
Tumor-infiltrating Lymphocytes
100%
Adoptive Cell Therapy
51%
Tumor-infiltrating Lymphocyte Therapy
38%
Metastatic Melanoma
33%
Programmed Death-ligand 1 (PD-L1)
31%
Checkpoint Inhibitors
29%
Melanoma
27%
Ovarian Cancer
21%
Inhibitor Resistant
19%
T Cells
17%
Checkpoint Inhibition
17%
Dendritic Cell Vaccine
16%
Tumor Fragment
15%
Chemotherapy
15%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
14%
Tumor Antigen
13%
Advanced Melanoma
13%
Solid Cancer
12%
Ipilimumab
12%
Immune Monitoring
10%
Cancer Patients
10%
Immune System
10%
Dendritic Cells
10%
Tumor Regression
10%
Tumor
10%
Cell-based
9%
Malignant Melanoma
9%
Phase II Trial
9%
Cancer Immunotherapy
8%
Anti-PD-1
8%
Anti-CTLA-4
8%
Tumor-specific Immune Response
8%
Immune Response
7%
CD8+ Tumor-infiltrating Lymphocytes
7%
Clinical Response
7%
Specific T Cells
7%
Cancer Vaccine
7%
Clinical Efficacy
7%
Cancer Types
7%
Complete Response
7%
CD8+ T Cells
7%
Interleukin-2
7%
Anti-programmed Death 1
7%
Cyclophosphamide
7%
Immune Checkpoint Inhibitors
7%
Non-melanoma
6%
Autologous Tumors
6%
CTLA-4 Blockade
6%
Metastatic Ovarian Cancer
6%
Future Role
6%
Medicine and Dentistry
Tumor Infiltrating Lymphocyte
97%
Cell Therapy
43%
Neoplasm
31%
Nodular Melanoma
30%
T Cell
29%
Ovarian Cancer
25%
Metastatic Melanoma
22%
Melanoma
19%
Ex Vivo
18%
Malignant Neoplasm
15%
CTLA-4
15%
Clinical Trial
13%
Ipilimumab
13%
CD8 Antigen
10%
Immunotherapy
9%
Tumor Regression
9%
Cytotoxic T-Cell
8%
Immune Response
8%
Programmed Death-Ligand 1
8%
Programmed Death 1 Receptor
7%
Tumor Antigen
7%
Disease
7%
Cancer Types
6%
Immunity
6%
Biological Marker
6%
Brain Metastasis
6%
Immune Reconstitution
6%
Nonmyeloablative Conditioning
6%
Tumor Immune Microenvironment
6%
Hope
6%
Bone Marrow Toxicity
6%
Cancer Immunotherapy
6%
Docetaxel
6%
Castration Resistant Prostate Cancer
6%
Dendritic Cell
6%
Disease Exacerbation
6%
Tumor Recurrence
6%
4 Iodo 2,5 Dimethoxyamphetamine
6%
Cost-Effectiveness Analysis
6%
Health Care Cost
6%
Immune Checkpoint Blockade
6%
Phase III and IV Trials
6%
Infusion
6%
Progression Free Survival
6%
Immune Checkpoint Inhibitor
5%
Interleukin 2
5%
Metastatic Carcinoma
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
81%
Melanoma
41%
Malignant Neoplasm
23%
Metastatic Melanoma
19%
Ipilimumab
17%
Ovary Cancer
12%
Clinical Trial
10%
Immunotherapy
10%
Tumor Regression
9%
Disease
9%
Vaccination Policy
8%
Chemotherapy
7%
Cyclophosphamide
7%
Biological Marker
6%
Castration Resistant Prostate Cancer
6%
Dendritic Cell Vaccine
6%
Brain Metastasis
6%
Phase III Trials
6%
Docetaxel
6%
Progression Free Survival
5%